On December 10th, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: CRDA®) Approved by the National Medical Products Administration (NMPA) of China, the combination of radiotherapy and chemotherapy is used for the treatment of stage III-IVA cervical cancer patients in the International Federation of Obstetrics and Gynecology (FIGO) 2014. The approval of this new indication is based on data from the global phase III clinical trial KEYNOTE-A18.